- Home
- SKLZ vs OBIO Comparison
SKLZ vs OBIO Comparison
Compare SKLZ & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKLZ
- OBIO
- Stock Information
- Founded
- SKLZ 2012
- OBIO 2017
- Country
- SKLZ United States
- OBIO United States
- Employees
- SKLZ N/A
- OBIO N/A
- Industry
- SKLZ EDP Services
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- SKLZ Technology
- OBIO Health Care
- Exchange
- SKLZ Nasdaq
- OBIO Nasdaq
- Market Cap
- SKLZ 136.4M
- OBIO 118.8M
- IPO Year
- SKLZ N/A
- OBIO N/A
- Fundamental
- Price
- SKLZ $8.54
- OBIO $2.55
- Analyst Decision
- SKLZ Buy
- OBIO Strong Buy
- Analyst Count
- SKLZ 1
- OBIO 4
- Target Price
- SKLZ $14.00
- OBIO $14.67
- AVG Volume (30 Days)
- SKLZ 105.8K
- OBIO 451.7K
- Earning Date
- SKLZ 08-07-2025
- OBIO 08-12-2025
- Dividend Yield
- SKLZ N/A
- OBIO N/A
- EPS Growth
- SKLZ N/A
- OBIO N/A
- EPS
- SKLZ N/A
- OBIO N/A
- Revenue
- SKLZ $93,320,000.00
- OBIO $2,944,000.00
- Revenue This Year
- SKLZ $17.44
- OBIO $19.83
- Revenue Next Year
- SKLZ $12.03
- OBIO $12.53
- P/E Ratio
- SKLZ N/A
- OBIO N/A
- Revenue Growth
- SKLZ N/A
- OBIO 41.61
- 52 Week Low
- SKLZ $3.54
- OBIO $2.37
- 52 Week High
- SKLZ $9.11
- OBIO $7.04
- Technical
- Relative Strength Index (RSI)
- SKLZ 58.33
- OBIO 42.61
- Support Level
- SKLZ $8.10
- OBIO $2.50
- Resistance Level
- SKLZ $9.11
- OBIO $2.75
- Average True Range (ATR)
- SKLZ 0.50
- OBIO 0.14
- MACD
- SKLZ 0.03
- OBIO -0.01
- Stochastic Oscillator
- SKLZ 77.29
- OBIO 42.50
About SKLZ Skillz Inc.
Skillz Inc is a mobile game development company. It is engaged in re-inventing competitive mobile gaming and thereby expanding the mobile gaming market. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The company's reportable business segments are; the Skillz segment and the Aarki segment. The majority of its revenue is generated from the Skillz segment which is an eSports gaming platform, enabling game developers to monetize their content through multi-player competition. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.